EP4724472A2 - Duale glp-1/gip-, glp-1/gcg-doppel- und glp-1/gip/gcg-dreifachrezeptoragonisten - Google Patents
Duale glp-1/gip-, glp-1/gcg-doppel- und glp-1/gip/gcg-dreifachrezeptoragonistenInfo
- Publication number
- EP4724472A2 EP4724472A2 EP24734139.9A EP24734139A EP4724472A2 EP 4724472 A2 EP4724472 A2 EP 4724472A2 EP 24734139 A EP24734139 A EP 24734139A EP 4724472 A2 EP4724472 A2 EP 4724472A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- moiety
- amino
- absent
- group
- spil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202321039646 | 2023-06-09 | ||
| PCT/IB2024/055620 WO2024252367A2 (en) | 2023-06-09 | 2024-06-07 | Novel glp-1/gip dual and glp-1/gcg dual receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4724472A2 true EP4724472A2 (de) | 2026-04-15 |
Family
ID=91585443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24734138.1A Pending EP4724471A1 (de) | 2023-06-09 | 2024-06-07 | Duale glp-1/gip-, glp-1/gcg-doppel- und glp-1/gip/gcg-dreifachrezeptoragonisten |
| EP24734139.9A Pending EP4724472A2 (de) | 2023-06-09 | 2024-06-07 | Duale glp-1/gip-, glp-1/gcg-doppel- und glp-1/gip/gcg-dreifachrezeptoragonisten |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24734138.1A Pending EP4724471A1 (de) | 2023-06-09 | 2024-06-07 | Duale glp-1/gip-, glp-1/gcg-doppel- und glp-1/gip/gcg-dreifachrezeptoragonisten |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP4724471A1 (de) |
| KR (1) | KR20260022948A (de) |
| CN (2) | CN121263433A (de) |
| AU (1) | AU2024284396A1 (de) |
| MX (1) | MX2025014772A (de) |
| WO (2) | WO2024252367A2 (de) |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| RS56173B1 (sr) * | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
| KR20140043793A (ko) | 2011-06-22 | 2014-04-10 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-작용물질 |
| IN2014MN02304A (de) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| TWI617574B (zh) * | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑 |
| SI3004155T1 (sl) | 2013-05-28 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Peptidna spojina |
| CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| TWI582109B (zh) | 2015-01-09 | 2017-05-11 | 美國禮來大藥廠 | Ｇｉｐ及ｇｌｐ－１共促效劑化合物 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| TWI700291B (zh) * | 2015-06-22 | 2020-08-01 | 美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| SG11201805586SA (en) | 2015-12-31 | 2018-07-30 | Hanmi Pharmaceutical Co Ltd | Triple glucagon/glp-1/gip receptor agonist |
| ES2983409T3 (es) | 2016-03-10 | 2024-10-23 | Medimmune Ltd | Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica |
| US11566057B2 (en) * | 2017-09-25 | 2023-01-31 | Merck Sharp & Dohme Llc | Long-acting co-agonists of the glucagon and GLP-1 receptors |
| CN109836488B (zh) * | 2017-11-24 | 2022-08-23 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的胰高血糖素类似物 |
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| MX2020010505A (es) | 2018-04-05 | 2021-01-15 | Sun Pharmaceutical Ind Ltd | Analogos novedosos de glp-1. |
| KR20240051304A (ko) | 2018-07-23 | 2024-04-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
| CN119499352A (zh) | 2018-07-23 | 2025-02-25 | 伊莱利利公司 | 使用gip/glp1共激动剂用于糖尿病的方法 |
| TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| PE20231309A1 (es) | 2020-10-17 | 2023-08-24 | Sun Pharmaceutical Ind Ltd | Agonistas duales glp-1/gip |
| TW202313974A (zh) * | 2021-06-08 | 2023-04-01 | 瑞典商阿斯特捷利康公司 | 用於治療肝病之組合療法 |
| CN115975057B (zh) * | 2023-03-16 | 2023-05-16 | 杭州信海医药科技有限公司 | 一种可妥度肽的固相合成方法 |
-
2024
- 2024-06-07 KR KR1020257041460A patent/KR20260022948A/ko active Pending
- 2024-06-07 WO PCT/IB2024/055620 patent/WO2024252367A2/en not_active Ceased
- 2024-06-07 EP EP24734138.1A patent/EP4724471A1/de active Pending
- 2024-06-07 EP EP24734139.9A patent/EP4724472A2/de active Pending
- 2024-06-07 CN CN202480038209.9A patent/CN121263433A/zh active Pending
- 2024-06-07 CN CN202480038210.1A patent/CN121285571A/zh active Pending
- 2024-06-07 AU AU2024284396A patent/AU2024284396A1/en active Pending
- 2024-06-07 WO PCT/IB2024/055618 patent/WO2024252366A1/en not_active Ceased
-
2025
- 2025-12-08 MX MX2025014772A patent/MX2025014772A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4724471A1 (de) | 2026-04-15 |
| WO2024252366A1 (en) | 2024-12-12 |
| CN121285571A (zh) | 2026-01-06 |
| WO2024252367A3 (en) | 2025-02-13 |
| AU2024284396A1 (en) | 2026-01-08 |
| WO2024252367A2 (en) | 2024-12-12 |
| MX2025014772A (es) | 2026-01-07 |
| CN121263433A (zh) | 2026-01-02 |
| KR20260022948A (ko) | 2026-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2559320C2 (ru) | Новые аналоги глюкагона | |
| CA3195155A1 (en) | Glp-1/gip dual agonists | |
| JP7250814B2 (ja) | 新規ｇｌｐ－１類似体 | |
| EP2124974B1 (de) | Glocagonanaloga mit erhöhter löslichkeit in physiologischen ph-puffern | |
| US20240424063A1 (en) | Long acting glp-1/gip dual agonists | |
| SG172170A1 (en) | Glucagon analogues | |
| WO2012167744A1 (en) | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof | |
| WO2014049610A2 (en) | Peptides as gip, glp-1 and glucagon receptors triple-agonist | |
| WO2007049941A1 (en) | Bioactive substance carrier for in vivo stable delivery tehreof, conjugate containing the same, and method of in vivo stable delivery of the bioactive substance | |
| EP4724472A2 (de) | Duale glp-1/gip-, glp-1/gcg-doppel- und glp-1/gip/gcg-dreifachrezeptoragonisten | |
| CN115873096B (zh) | 一种胰高血糖素糖肽-1和胰高血糖素受体双重激动多肽及其应用 | |
| EP4638481A1 (de) | Triple agonisten des glp1/gip/npy2-rezeptors | |
| CA2606894A1 (en) | Novel compounds as glp-i agonists | |
| CN116589536B (zh) | 一类长效glp-1/gip受体双重激动剂及其应用 | |
| CN115232200B (zh) | 长效化Exendin-4类似物及其应用 | |
| CN116514952B (zh) | 一类glp-1类似物及其应用 | |
| EA053025B1 (ru) | Двойные агонисты glp-1/gip | |
| CN117186189A (zh) | 一种兼具降糖和减重作用的glp-1/cck-1受体双重激动多肽及其应用 | |
| CN115819619A (zh) | 一类glp-1/y2受体双重激动剂及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20251222 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |